Reuters logo
BRIEF-Kindred Biosciences receives early approval of effectiveness technical section from FDA for Mirataz
February 6, 2017 / 2:28 PM / 10 months ago

BRIEF-Kindred Biosciences receives early approval of effectiveness technical section from FDA for Mirataz

Feb 6 (Reuters) - Kindred Biosciences Inc

* Kindred biosciences receives early approval of effectiveness technical section from fda for mirataz new animal drug application

* Kindred biosciences inc - has received a technical section complete letter for effectiveness from u.s. Food and drug administration

* Kindred biosciences inc says expect approval of mirataz in second half of 2017 assuming no unforeseen delays in review process

* Kindred biosciences inc - basis for complete letter was a multicenter, randomized, double-blind, placebo-controlled pivotal field study Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below